Skip to main content

Table 1 Efficacy parameters used in the model

From: Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

Comparators

Response

Odds ratio

Source

Mean

SE

Episodic migraine

 Erenumab + BSC

37%

-

-

Trial Data [28,29,30]

 Topiramate + BSC

18%

2.76

1.16

HER-MES study [26]

Chronic migraine

 Erenumab + BSC

42%

-

-

Trial Data [31]

 Placebo + BSC

17%

2.27

0.00

Trial Data [31]

  1. SE Standard error, BSC best supportive care
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us